KYMR Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
-100.0%
65.0M
+89.1%
34.4M
+1097.4%
2.9M
+3.8%
2.8M
Cost of Revenue
0
0
0
0
0
Gross Profit
0
-100.0%
65.0M
+89.1%
34.4M
+1097.4%
2.9M
+3.8%
2.8M
Operating Expenses
147.2M
+4.7%
140.6M
+18.6%
118.6M
+17.7%
100.8M
+5.8%
95.3M
R&D
128.5M
+7.6%
119.5M
+21.7%
98.2M
+17.1%
83.8M
+13.1%
74.1M
SG&A
18.7M
-11.4%
21.1M
+3.8%
20.4M
+20.2%
16.9M
-2.3%
17.3M
Operating Income
-147232000
-94.7%
-75607000
+10.2%
-84215000
+14.0%
-97896000
-5.8%
-92521000
EBITDA
-145209000
-97.4%
-73577000
+10.5%
-82193000
+14.3%
-95864000
-10.8%
-86517000
Net Income
-131999000
-115.6%
-61211000
+11.6%
-69234000
+20.4%
-86981000
-5.8%
-82175000
EPS (Basic)
$-1.32
-112.9%
$-0.62
+12.7%
$-0.71
+26.8%
$-0.97
-3.2%
$-0.94
EPS (Diluted)
$-1.32
-112.9%
$-0.62
+12.7%
$-0.71
+26.8%
$-0.97
-3.2%
$-0.94
Shares (Diluted)
100.1M
+2.0%
98.2M
+0.7%
97.5M
+8.3%
90.1M
+3.2%
87.3M
Kymera Therapeutics (KYMR) — Financials